Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance

References

• Grzybowski A, Ruamviboonsuk V. Pharmacological treatment in presbyopia. J Clin Med 2022; 11: 1385. doi:10.3390/jcm11051385.
   PubMed Web of Science ®Google Scholar
• Institute for Quality and Efficiency in Health Care (IQWiG). Presbyopia: overview. [accessed 2023 Aug 14]. https://www.ncbi.nlm.nih.gov/books/NBK423833/?report=reader#_NBK423833_pubdet.
   Google Scholar
• American Optometric Association. Optometric clinical practice guideline - care of the patient with presbyopia. [ accessed 2023 Aug 14]. https://www.sdeyes.org/docs/CPG-17.pdf.
   Google Scholar
• Institute for Quality and Efficiency in Health Care (IQWiG). How can presbyopia be corrected? [accessed 2023 Aug 14]. https://www.ncbi.nlm.nih.gov/books/NBK423827/?report=reader.
   Google Scholar
• United Nations Department of Economic and Social Affairs. World population ageing 2020 highlights. [accessed 2023 Aug 14]. https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Sep/un_pop_2020_pf_ageing_10_key_messages.pdf.
   Google Scholar
• Fricke TR, Tahhan N, Resnikoff S et al. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis, and modelling. Ophthalmology 2018; 125: 1492–1499. doi:10.1016/j.ophtha.2018.04.013.
   PubMed Web of Science ®Google Scholar
• McGee S, Waring GO IV. Pilocarpine hydrochloride ophthalmic solution 1.25%: an innovative prescription eye drop for the treatment of presbyopia. touchREVIEWS Ophthalmol 2022; 16: 54–62. doi:10.17925/USOR.2022.16.2.54.
   Google Scholar
• Allergan. VUITYTM (pilocarpine hydrochloride ophthalmic solution) 1.25%, for topical ophthalmic use [prescribing info]. [accessed 2023 Aug 14]. https://www.rxabbvie.com/pdf/vuity_pi.pdf.
   Google Scholar
• AbbVie. VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the first and only FDA-approved eye drop to treat age-related blurry near vision (presbyopia), is now available. [accessed 2023 Aug 14]. https://news.abbvie.com/news/press-releases/vuity-pilocarpine-hci-ophthalmic-solution-125-first-and-only-fda-approved-eye-drop-to-treat-age-related-blurry-near-vision-presbyopia-is-now-available.htm.
   Google Scholar
• National Library of Medicine. ClinicalTrials.Gov glossary terms. [accessed 2023 Jun 21]. https://clinicaltrials.gov/study-basics/glossary.
   Google Scholar
• Waring GO IV, Price FW Jr, FW P Jr, Wirta D et al. Safety and efficacy of AGN-190584 in individuals with presbyopia: the GEMINI 1 phase 3 randomized clinical trial. JAMA Ophthalmol 2022; 140: 363–371. doi:10.1001/jamaophthalmol.2022.0059.
   PubMed Web of Science ®Google Scholar
• Alcon Laboratories. Isopto® carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2% and 4% [prescribing info]. [accessed 2023 Aug 14]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf.
   Google Scholar
• Wood JM. Age and visual impairment decrease driving performance as measured on a closed-road circuit. Hum Factors 2002; 44: 482–494. doi:10.1518/0018720024497664.
   PubMed Web of Science ®Google Scholar
• Wood JM, Collins MJ, Chaparro A et al. Differential effects of refractive blur on day and nighttime driving performance. Invest Ophthalmol Vis Sci 2014; 55: 2284–2289. doi:10.1167/iovs.13-13369.
   PubMed Web of Science ®Google Scholar
• Wood J, Chaparro A, Carberry T et al. Effect of simulated visual impairment on nighttime driving performance. Optom Vis Sci 2010; 87: 379–386. doi:10.1097/OPX.0b013e3181d95b0d.
   PubMed Web of Science ®Google Scholar
• Wood J, Chaparro A, Hickson L. Interaction between visual status, driver age and distracters on daytime driving performance. Vision Res 2009; 49: 2225–2231. doi:10.1016/j.visres.2009.06.017.
   PubMed Web of Science ®Google Scholar
• Buch JR, Toubouti Y, Cannon J. Randomized crossover trial evaluating the impact of senofilcon A photochromic lens on driving performance. Optom Vis Sci 2020; 97: 15–23. doi:10.1097/opx.0000000000001466.
   PubMed Web of Science ®Google Scholar
• American National Standards Institute (ANSI). 2017. ANSI requirements on night driving performance for multifocal IOL. ANSI Z80.12-2007 (R2017).
   Google Scholar
• Bamdad S, Ahmad Razavizadegan S, Farvardin M et al. Vision-related quality of life after bilateral implantation of monofocal and multifocal intraocular lenses. J Ophthalmic Vis Res 2022; 17: 19–26. doi:10.18502/jovr.v17i1.10166.
   PubMed Web of Science ®Google Scholar
• Ozulken K, Kiziltoprak H, Yuksel E et al. A comparative evaluation of diffractive trifocal and new refractive/extended depth of focus intraocular lenses for refractive lens exchange. Curr Eye Res 2021; 46: 811–817. doi:10.1080/02713683.2020.1833347.
   PubMed Web of Science ®Google Scholar
• Mai EL, Lian IB, Chang DC. Assessment of contrast sensitivity loss after intrastromal femtosecond laser and LASIK procedure. Int J Ophthalmol 2016; 9: 1798–1801. doi:10.18240/ijo.2016.12.16.
   PubMed Web of Science ®Google Scholar
• Chu BS, Wood JM, Collins MJ. The effect of presbyopic vision corrections on nighttime driving performance. Invest Ophthalmol Vis Sci 2010; 51: 4861–4866. doi:10.1167/iovs.10-5154.
   PubMed Web of Science ®Google Scholar
• Chu BS, Wood JM, Collins MJ. Effect of presbyopic vision corrections on perceptions of driving difficulty. Eye Contact Lens 2009; 35: 133–143. doi:10.1097/ICL.0b013e3181a1435e.
   PubMed Web of Science ®Google Scholar
• Berry S, Mangione CM, Lindblad AS et al. Development of the National Eye Institute refractive error correction quality of life questionnaire: focus groups. Ophthalmology 2003; 110: 2285–2291. doi:10.1016/j.ophtha.2003.08.021.
   PubMed Web of Science ®Google Scholar
• Johnston J, Feulner L, Davidson J et al. Pilocarpine HCl ophthalmic solution 1.25% in moderate presbyopia: a post hoc analysis of the GEMINI phase 3 trials. American Academy of Optometry (AAOpt) 2022 Annual Meeting; 2022; San Diego, CA, USA.
   Google Scholar